On December 21, 2012, Alexza Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration approved ADASUVEŽ (loxapine) Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.

(d) Exhibits.

Exhibit Number                                 Description

99.1                   Press Release titled "U.S. FDA Approves Alexza's ADASUVEŽ
                       (loxapine) Inhalation Powder for the Acute Treatment of
                       Agitation Associated with Schizophrenia or Bipolar I
                       Disorder in Adults," dated December 21, 2012.